Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-11-20 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司2019年第二期股票期权激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告
Director's Dealing Classification · 95% confidence The document is a self-inspection report regarding insider trading and stock transactions by insiders and incentive plan participants related to a 2019 stock option incentive plan. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and details the investigation and findings about insider trading activities. The document is a formal announcement about insider dealings and compliance with insider trading regulations, not a financial report, earnings release, or management discussion. It fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is under 5,000 characters and contains detailed insider transaction information, confirming it is a DIRS filing rather than a mere announcement or regulatory filing.
2019-11-20 Chinese
2019年第四次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the convening, attendance, voting procedures, and results of the 2019 fourth extraordinary general meeting of shareholders of the company. It details the meeting notice, attendance, voting methods, agenda items, and voting results. The document does not contain financial statements or management discussion of financial results but focuses on the legal compliance and validation of the shareholder meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, specifically a legal opinion on the shareholder meeting. Therefore, it fits best under the category Legal Proceedings Report (LTR). The document length (6574 characters) and content confirm it is not a brief announcement or a full annual/interim report but a standalone legal opinion report.
2019-11-20 Chinese
2019年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2019 fourth extraordinary general meeting of shareholders of 健帆生物科技集团股份有限公司. It includes information about the meeting date, attendance, voting results on multiple proposals, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on the official voting results and decisions made during the shareholders' meeting, such as approval of stock option plans, changes in audit institutions, and amendments to the company bylaws. There is no indication that this is a full annual or interim report, audit report, or earnings release. The document is not a presentation or a proxy solicitation but an official announcement of voting results from a shareholders' meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (3623 characters) and detailed voting data support this classification with high confidence.
2019-11-20 Chinese
监事会关于2019年第二期股票期权激励计划激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement from the supervisory board regarding the verification and public disclosure of the list of incentive recipients under the company's 2019 second stock option incentive plan. It details the process of public notice, verification of eligibility, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data, nor is it a report of financial results or management discussion. It is a regulatory announcement related to stock option incentive plan participants and their compliance verification. The document length is short (1703 characters), and it is an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-11-15 Chinese
上海荣正投资咨询股份有限公司关于公司2019年第二期股票期权激励计划（草案）之独立财务顾问报告
Capital/Financing Update Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" regarding the "2019 Second Stock Option Incentive Plan (Draft)" of the company 健帆生物科技集团股份有限公司. It contains detailed analysis and opinions on the stock option incentive plan, including legal compliance, feasibility, scope of incentive targets, stock option quantities, exercise conditions, financial impact, and performance assessment. The document is comprehensive and lengthy (15,000 characters), indicating it is the full report rather than a brief announcement. It is not an annual or quarterly financial report, nor an earnings release or management discussion. It is a specialized advisory report related to a capital/financing activity (stock option incentive plan). Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-11-03 Chinese
2019年第二期股票期权激励计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary and draft of a 2019 second stock option incentive plan for a company named 健帆生物科技集团股份有限公司. It includes extensive information about the stock option plan, including legal basis, number of options, allocation, exercise price, conditions for exercise, performance targets, accounting treatment, and procedures for adjustments and changes. The document is lengthy (15,000 characters) and contains substantive content about the stock option incentive plan itself, not merely an announcement or a brief summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a detailed plan document related to capital/financing activities, specifically a stock option incentive plan which is a form of equity compensation and capital structure update. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-11-03 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.